Organization · Venture Capital
Monograph Capital
Monograph Capital is a venture capital firm based in London and San Francisco, specializing in early-stage investments in life sciences companies focused on therapeutics, diagnostics, and digitally-enabled healthcare solutions.
Overview
What Monograph Capital does
What Monograph Capital is
Monograph Capital is a venture capital firm based in London and San Francisco, specializing in early-stage investments in life sciences companies focused on therapeutics, diagnostics, and digitally-enabled healthcare solutions.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2021
- Approximate age
- About 5 years
- Structured capabilities
- Funder
- Last reviewed
- April 9, 2026
Official channels
Find Monograph Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
Monograph Capital as a funder
Investment thesis
Monograph Capital invests in early-stage life sciences companies, focusing on therapeutics, diagnostics, and digitally-enabled healthcare, aiming to translate scientific advancements into global healthcare solutions.
Focus narrative
Monograph Capital focuses on early-stage life sciences companies, particularly those innovating in therapeutics, diagnostics, and digitally-enabled healthcare. The firm emphasizes sourcing leading scientific innovations and aims to support the development of strong companies across North America and Europe.
Value beyond capital
Monograph Capital adds value to its portfolio companies by leveraging its extensive network in the life sciences sector, providing strategic guidance, and facilitating connections with leading scientists and institutions. The firm actively participates in the development of its portfolio companies, often co-founding ventures alongside scientific innovators.
Focus and fit
- Stages
- Pre-seed · Seed · Seed+ · Series A · Series B
- Regions
- EuropeNorth America
Availability
- Currently deploying
- Yes
Portfolio and track record
Portfolio context
Monograph Capital's portfolio includes notable companies such as: Ascend Advanced Therapies: A gene-to-GMP contract development and manufacturing organization founded in December 2021, focused on improving gene therapy technologies. Autobahn: A clinical-stage biotechnology company based in San Diego, developing therapies for depressive illnesses, currently completing Phase 2 studies. AviadoBio: A UK-based gene therapy company targeting neurodegenerative diseases, co-led a Series A financing round in November 2021. Maxion Therapeutics: A preclinical biotechnology company developing antibody drugs against ion channels and GPCRs, co-led a Seed funding round in February 2025. Nocion Therapeutics: A clinical-stage biotechnology company developing an inhaled small molecule therapeutic for chronic cough, co-led a Series B financing in February 2024. Ollin Biosciences: Focused on therapies for vision-threatening conditions, established in 2023 with initial financing from Monograph and partners. ODAIA: An AI-powered commercial insights platform for pharmaceutical companies, co-led a Series B financing in April 2023. Ouro Medicines: Developing immune reset therapeutics for chronic autoimmune diseases, co-led a Series A financing in December 2024. Prolynx: A biotechnology company focused on ultra-long-acting medicines for obesity, with Series A financing led by Monograph. Sudo: A clinical-stage neuro-immunology company advancing TYK2 inhibitors, participated in Series B financing in December 2023.
Common questions
What to know about Monograph Capital
Upseed classifies Monograph Capital under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 9, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.